LEADER 05618nam 2200721 450 001 9910132344003321 005 20200520144314.0 010 $a3-527-67615-5 010 $a3-527-67613-9 010 $a3-527-67614-7 035 $a(CKB)3710000000222912 035 $a(EBL)1767041 035 $a(SSID)ssj0001413784 035 $a(PQKBManifestationID)11870829 035 $a(PQKBTitleCode)TC0001413784 035 $a(PQKBWorkID)11417735 035 $a(PQKB)11606358 035 $a(MiAaPQ)EBC1767041 035 $a(MiAaPQ)EBC4044551 035 $a(Au-PeEL)EBL1767041 035 $a(CaPaEBR)ebr10909201 035 $a(CaONFJC)MIL637255 035 $a(OCoLC)888352788 035 $a(PPN)189378581 035 $a(EXLCZ)993710000000222912 100 $a20140901h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aNovel antimicrobial agents and strategies /$fedited by David A. Phoenix, Frederick Harris and Sarah R. Dennison ; contributors Waqar Ahmed [and thirty one others] 210 1$aWeinheim, Germany :$cWiley-VCH,$d2015. 210 4$dİ2015 215 $a1 online resource (439 p.) 300 $aDescription based upon print version of record. 311 $a3-527-33638-9 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aNovel Antimicrobial Agents and Strategies; Contents; List of Contributors; Preface; Chapter 1 The Problem of Microbial Drug Resistance; 1.1 Introduction; 1.2 History of the Origins, Development, and Use of Conventional Antibiotics; 1.3 Problems of Antibiotic Resistance; 1.4 Multiple Drug-Resistant (MDR), Extensively Drug-Resistant (XDR), and Pan-Drug-Resistant (PDR) Organisms; 1.5 MDR Mechanisms of Major Pathogens; 1.6 Antimicrobial Stewardship Programs; 1.7 Discussion; Acknowledgment; References; Chapter 2 Conventional Antibiotics -- Revitalized by New Agents; 2.1 Introduction 327 $a2.2 Conventional Antibiotics2.3 The Principles of Combination Antibiotic Therapy; 2.4 Antibiotic Resistance Breakers: Revitalize Conventional Antibiotics; 2.4.1 ?-Lactamase Inhibitors; 2.4.2 Aminoglycoside-Modifying Enzyme Inhibitors; 2.4.3 Antibiotic Efflux Pumps Inhibitors; 2.4.4 Synergy Associated with Bacterial Membrane Permeators; 2.5 Discussion; Acknowledgments; References; Chapter 3 Developing Novel Bacterial Targets: Carbonic Anhydrases as Antibacterial Drug Targets; 3.1 Introduction; 3.2 Carbonic Anhydrases; 3.3 CA Inhibitors; 3.4 Classes of CAs Present in Bacteria 327 $a3.5 Pathogenic Bacterial CAs3.6 ?-CAs in Pathogenic Bacteria; 3.7 ?-CAs in Pathogenic Bacteria; 3.8 ?-CAs from Pathogenic Bacteria; 3.9 Conclusions; References; Chapter 4 Magainins -- A Model for Development of Eukaryotic Antimicrobial Peptides (AMPs); 4.1 Introduction; 4.2 Magainins and Their Antimicrobial Action; 4.3 Magainins as Antibiotics; 4.4 Other Antimicrobial Uses of Magainins; 4.5 Future Prospects for Magainins; References; Chapter 5 Antimicrobial Peptides from Prokaryotes; 5.1 Introduction; 5.2 Bacteriocins; 5.2.1 Microcins -- Peptide Bacteriocins from Gram-Negative Bacteria 327 $a5.2.2 Lanthibiotics -- Post-translationally Modified Peptides from Gram-Positive Bacteria5.2.3 Non-modified Peptides from Gram-Positive Bacteria; 5.3 Applications of Prokaryotic AMPs; 5.3.1 Food Biopreservation; 5.3.2 Bacteriocinogenic Probiotics; 5.3.3 Clinical Application; 5.3.4 Applications in Dental Care; 5.4 Development and Discovery of Novel AMP; References; Chapter 6 Peptidomimetics as Antimicrobial Agents; 6.1 Introduction; 6.2 Antimicrobial Peptidomimetics; 6.2.1 Peptoids; 6.2.2 ?-Peptides; 6.2.3 Arylamides; 6.2.4 ?-Peptoid--Peptide Hybrid Oligomers 327 $a6.2.5 Oligourea and ? 4-Peptide-Based Oligomers6.2.6 AApeptides; 6.2.6.1 ?-AApeptides; 6.2.6.2 ?-AApeptides; 6.3 Discussion; Acknowledgments; References; Chapter 7 Synthetic Biology and Therapies for Infectious Diseases; 7.1 Current Challenges in the Treatment of Infectious Diseases; 7.2 Introduction to Synthetic Biology; 7.3 Vaccinology; 7.3.1 Genetic Engineering and Vaccine Development; 7.3.2 Rational Antigen Design Through Reverse Vaccinology; 7.4 Bacteriophages: A Re-emerging Solution?; 7.4.1 A Brief History of Bacteriophages 327 $a7.4.2 Addressing the Problem of the Restricted Host Range of Phages 330 $aBy integrating knowledge from pharmacology, microbiology, molecular medicine, and engineering, researchers from Europe, the U.S. and Asia cover a broad spectrum of current and potential antimicrobial medications and treatments. The result is a comprehensive survey ranging from small-molecule antibiotics to antimicrobial peptides and their engineered mimetics, from enzymes to nucleic acid therapeutics, from metallic nanoparticles to photo- and sonosensitizers and to phage therapy. In each case, the therapeutic approaches are compared in terms of their mechanisms, likelihood to induce resistance 606 $aDisinfection and disinfectants 606 $aAnti-infective agents 606 $aSterilization 615 0$aDisinfection and disinfectants. 615 0$aAnti-infective agents. 615 0$aSterilization. 676 $a614.48 702 $aPhoenix$b David A. 702 $aHarris$b Frederick 702 $aDennison$b Sarah R. 702 $aAhmed$b Waqar 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910132344003321 996 $aNovel antimicrobial agents and strategies$92125657 997 $aUNINA